@article {38929,
	title = {Drug-drug interactions between COVID-19 drug therapies and antidepressants},
	journal = {Expert Opin Drug Metab Toxicol},
	volume = {19},
	number = {12},
	year = {2023},
	note = {10.1080/17425255.2023.2280750},
	month = {Dec},
	pages = {937-950},
	edition = {20240112},
	abstract = {INTRODUCTION: Antidepressants are widely used for the pharmacological treatment of anxiety and mood disorders. Since the eruption of the SARS-COV-2 pandemic and the later development of targeted treatments against COVID-19, inevitably many patients receive antidepressants as well as targeted treatments against COVID-19 against COVID-19. Co-administration of antidepressants with COVID-19 therapeutics has the potential of drug-drug interactions, of varying severity and clinical significance. AREAS COVERED: This is a curated narrative review of the current state of the art regarding drug-drug interactions between COVID-19 therapeutics and medications licensed for the pharmacotherapy of depression. A systematic search of electronic databases, using as keywords the international nonproprietaty names of currently approved COVID-19 therapeutics and antidepressants was performed, and additionally online interaction checker tools were consulted. Derived data were synthesized for each COVID-19 therapeutic and presented with up-to-date guidance. EXPERT OPINION: Several COVID-19 therapeutics have potential for drug-drug interactions with antidepressants. Remdesivir and Nirmatrelvir-Ritonavir have the higher risk, whereas several monoclonal antibodies appear safer. The most serious drug-drug interactions (serotonin syndrome and QTc prolongation) require close monitoring; however, DDI toward reducing the efficacy of antidepressants may be difficult to recognize. As COVID-19 treatment protocols take precedence, psychiatrists should exert flexibility in antidepressant use and proactively monitor treatment progress.},
	keywords = {*Covid-19, antidepressants, Antidepressive Agents/adverse effects, Antiviral Agents/adverse effects, anxiety, Covid-19, COVID-19 Drug Treatment, Depression, Drug Interactions, Humans, Ritonavir, SARS-CoV-2, Serotonin},
	isbn = {1742-5255},
	author = {Davoutis, E. and Panou, C and Stachika, N. and Dalla, C and Kokras, N}
}
